Table 2.
Clinical characteristics after 6 weeks of dapagliflozin and placebo treatment, respectively
| Placebo Mean ± SD (change from baseline) |
p-value vs. baseline | Dapagliflozin Mean ± SD (change from baseline) |
p-value vs. baseline | |
|---|---|---|---|---|
| BMI (kg/m2) | 29.9 ± 4.2 (+ 0.1) | 0.846 | 29.5 ± 4.1 (−0.3) | < 0.001 |
| HbA1c (%) | 6.79 ± 0.8 (+ 0.12) | 0.064 | 6.62 ± 0.7 (− 0.05) | 0.224 |
| Glucose | ||||
| Fasting (mg/dl) | 135 ± 32 (+ 2.0) | 0.325 | 114 ± 19 (−18) | < 0.001 |
| Postprandial† (mg/dl) | 180 ± 67 (+ 1.0) | 0.766 | 154 ± 46 (− 24) | < 0.001 |
| Office blood pressure | ||||
| Systolic (mmHg) | 129 ± 13 (− 0.1) | 0.340 | 126 ± 12 (− 4.0) | 0.015 |
| Diastolic (mmHg) | 79 ± 8.7 (− 1.0) | 0.827 | 78 ± 8.8 (− 2.0) | 0.058 |
| Heart rate (bpm) | 67.8 ± 9.6 (− 1.3) | 0.123 | 68.2 ± 10.6 (− 0.9) | 0.332 |
| 24-h ambulatory blood pressure | ||||
| Systolic (mmHg) | 129 ± 10.8 (− 0.5) | 0.172 | 126 ± 10.8 (−3.0) | 0.010 |
| Diastolic (mmHg) | 77.1 ± 7.3 (0.0) | 0.765 | 75.4 ± 7.7 (−2.0) | 0.024 |
| Heart rate (bpm) | 75.7 ± 9.5 (+ 1.4) | 0.997 | 74.1 ± 7.6 (− 0.8) | 0.849 |
| Haematocrit (%) | 40.3 ± 3.1 (+ 0.2) | 0.389 | 41.1 ± 2.9 (+ 1.0) | < 0.001 |
| Serum sodium conc. (mmol/l) | 138.1 ± 1.6 (− 0.5) | 0.034 | 138.3 ± 1.6 (− 0.3) | 0.308 |
| Urinary sodium excretion over 24 h (mmol/day) | 222.5 ± 103.6 (− 6.0) | 0.660 | 210.1 ± 71.2 (+ 6.5) | 0.586 |
N = 59. BMI body mass index, HbA1c glycated haemoglobin
†A standardised breakfast was given